Atlantic ImmediCare clinic opens in local Rite Aid
POCOMOKE CITY, Md. An Atlantic ImmediCare clinic opened its doors in Rite Aid Nov. 28, making for the second retail clinic operation launched by Atlantic General Hospital to open in November.
A basic office visit will cost $49. Atlantic ImmediCare does not accept insurance, however the company will file a claim on behalf of any Medicare patient. Reimbursement for the visit, if approved by Medicare, will be sent directly to the patient or policy holder, the company stated.
The two retail clinic openings are part of a partnership between Rite Aid and Atlantic General Hospital and Health System around three retail clinics announced in September. The third clinic is located in Milsboro, Del.
“The Atlantic ImmediCare clinics will complement the medication counseling and care provided by our pharmacists and provide the convenience of high-quality, affordable healthcare services to patients who won’t have to wait for an appointment to receive treatment for minor illnesses and get basic medical tests,” stated Robert Thompson, Rite Aid EVP pharmacy, at the time of the announcement. “Knowing they will receive the same quality healthcare they would expect from any Atlantic General Health System provider is a reassurance to all our patients.”
FDA accepts NDA for new Aricept formulation
WOODCLIFF LAKE, N.J. Eisai and Pfizer announced that the Food and Drug Administration has accepted for review Eisai’s new drug application for its Alzheimer’s disease treatment.
Once daily 23-mg Aricept (donepezil HCl extended release) tablets is a new higher dose formulation contains 23-mg of donepezil HCl in an extended release, matrix-type tablet with a delivery system that allows for gradual release of the drug. The NDA is based on a head-to-head clinical study comparing the 23-mg Aricept extended release tablet to the currently marketed once daily 10-mg Aricept (donepezil HCl) immediate release tablet. More than 1,400 patients with moderate to severe Alzheimer’s disease were enrolled in this global study.
Acceptance of the NDA indicates that the FDA has found the company’s submission to be sufficiently complete to review. Eisai and Pfizer believe this new formulation will potentially provide physicians, patients and their families with another option for the management of Alzheimer’s disease, the companies stated.
Study finds spike in morbid obesity rates among Type 2 diabetics
NEW YORK A Loyola University Health System study has found that 1-out-of-5 Type 2 diabetics is morbidly obese — approximately 100 lbs. or more overweight.
“The rate of morbid obesity among people with diabetes is increasing at a very alarming rate, and this has substantial public health implications,” said Dr. Holly Kramer, a kidney specialist and lead author of the study published online in the Journal of Diabetes and its Complications.
Kramer and colleagues examined data from the National Health and Nutrition Examination Surveys completed during the years 1976 to 2006. The surveys, known as NHANES, included interviews and physical examinations of representative samples of the U.S. population.
The study found a 141% increase in the rate of morbid obesity among adults with Type 2 diabetes between 1976 to 1980 and 2005 to 2006. More than 60% of U.S. adults with Type 2 diabetes are obese, and 20.7% are morbidly obese. Further, 1-in-3 African-American adults with Type 2 diabetes is morbidly obese.